Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.

BACKGROUND Type 3 long QT syndrome (LQT3) is the third most common form of LQT syndrome and is characterized by QT-interval prolongation resulting from a gain-of-function mutation in SCN5A. We aimed to establish a patient-specific human induced pluripotent stem cell (hiPSC) model of LQT3, which could be used for future drug testing and development of novel treatments for this inherited disorder. METHODS AND RESULTS Dermal fibroblasts obtained from a patient with LQT3 harboring a SCN5A mutation (c.5287G>A; p.V1763M) were reprogrammed to hiPSCs via repeated transfection of mRNA encoding OCT-4, SOX-2, KLF-4, C-MYC and LIN-28. hiPSC-derived cardiomyocytes (hiPSC-CMs) were obtained via cardiac differentiation. hiPSC-CMs derived from the patient's healthy sister were used as a control. Compared to the control, patient hiPSC-CMs exhibited dominant mutant SCN5A allele gene expression, significantly prolonged action potential duration or APD (paced CMs of control vs. patient: 226.50 ± 17.89 ms vs. 536.59 ± 37.1 ms; mean ± SEM, p < 0.005), an increased tetrodotoxin (TTX)-sensitive late or persistent Na(+) current (control vs. patient: 0.65 ± 0.11 vs. 3.16 ± 0.27 pA/pF; n = 9, p < 0.01), a positive shift of steady state inactivation and a faster recovery from inactivation. Mexiletine, a NaV1.5 blocker, reversed the elevated late Na(+) current and prolonged APD in LQT3 hiPSC-CMs. CONCLUSIONS We demonstrate that hiPSC-CMs derived from a LQT3 patient recapitulate the biophysical abnormalities that define LQT3. The clinical significance of such an in vitro model is in the development of novel therapeutic strategies and a more personalized approach in testing drugs on patients with LQT3.

[1]  Sungsam Gong,et al.  Next Generation Diagnostics in Inherited Arrhythmia Syndromes , 2012, Journal of Cardiovascular Translational Research.

[2]  G. Celano,et al.  Orphanet Journal of Rare Diseases BioMed Central Review Congenital long QT syndrome , 2008 .

[3]  A. Malliani,et al.  The long Q-T syndrome. , 1975, American heart journal.

[4]  S. Priori,et al.  Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome. , 1996, Circulation research.

[5]  P. Carmeliet,et al.  Altered Na+ Channels Promote Pause-Induced Spontaneous Diastolic Activity in Long QT Syndrome Type 3 Myocytes , 2006, Circulation research.

[6]  Silvia G. Priori,et al.  Sodium channel mutations and arrhythmias , 2009, Nature Reviews Cardiology.

[7]  M. Arita,et al.  Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells. , 1986, Life sciences.

[8]  M. Ackerman,et al.  SCN5A allelic expression imbalance in African-Americans heterozygous for the common variant p.Ser1103Tyr , 2010, BMC Medical Genetics.

[9]  Gordon Keller,et al.  Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics , 2013, The Journal of general physiology.

[10]  F. Chiang,et al.  A novel SCN5A mutation manifests as a malignant form of long QT syndrome with perinatal onset of tachycardia/bradycardia. , 2004, Cardiovascular research.

[11]  A. Wilde,et al.  A single Na(+) channel mutation causing both long-QT and Brugada syndromes. , 1999, Circulation research.

[12]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[13]  P. Guicheney,et al.  Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. , 2000, Cardiovascular research.

[14]  Guy Salama,et al.  Mouse models of long QT syndrome , 2007, The Journal of physiology.

[15]  G. Breithardt,et al.  Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. , 2003, Cardiovascular research.

[16]  Arthur J Moss,et al.  SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome , 1995, Cell.

[17]  Karl-Ludwig Laugwitz,et al.  Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.

[18]  M. Chung,et al.  Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. , 2004, Cardiovascular research.

[19]  S. Priori,et al.  Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients , 2007, Circulation.

[20]  J. Saiz,et al.  Effects of late sodium current enhancement during LQT-related arrhythmias. A simulation study , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

[21]  C Antzelevitch,et al.  Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. , 1997, Circulation.

[22]  Donald M Bers,et al.  Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.

[23]  Lior Gepstein,et al.  Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.

[24]  E. Behr,et al.  The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. , 2008, The Journal of clinical investigation.

[25]  P. C. Viswanathan,et al.  Gating-Dependent Mechanisms for Flecainide Action in SCN5A-Linked Arrhythmia Syndromes , 2001, Circulation.

[26]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[27]  Dan M Roden,et al.  Cardiac potassium channel dysfunction in sudden infant death syndrome. , 2007, Journal of molecular and cellular cardiology.

[28]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[29]  A. George,et al.  Pharmacological targeting of long QT mutant sodium channels. , 1997, The Journal of clinical investigation.

[30]  Dongrui Ma,et al.  Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine , 2012, Heart.

[31]  A. Moss,et al.  Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. , 2003, The Journal of clinical investigation.

[32]  A. George,et al.  Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Philip Wong,et al.  Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.

[34]  Ofer Binah,et al.  Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure , 2011, Journal of cellular and molecular medicine.

[35]  D. Malan,et al.  Cardiomyocytes Obtained From Induced Pluripotent Stem Cells With Long-QT Syndrome 3 Recapitulate Typical Disease-Specific Features In Vitro , 2011, Circulation research.

[36]  Jonathan A. Bernstein,et al.  Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.

[37]  C. Mummery,et al.  Cardiomyocytes Derived From Pluripotent Stem Cells Recapitulate Electrophysiological Characteristics of an Overlap Syndrome of Cardiac Sodium Channel Disease , 2012, Circulation.